Clinical Trials Logo

Filter by:
NCT ID: NCT04724785 Recruiting - Clinical trials for Hepatitis B, Chronic

Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients

REACH
Start date: December 1, 2020
Phase:
Study type: Observational

In the treatment of chronic hepatitis B (CHB), viral suppression is closely related to disease progression, and the lower the viral load, the lower the risk of progression to cirrhosis and hepatocellular carcinoma (HCC). In addition, a considerable number of patients in China are still using non-first-line antiviral therapy, such as adefovir dipivoxil, lamivudine, and telbivudine (ADV/LAM/LdT). About 25% of patients who received entecavir(ETV) treatment for more than half a year and confirmed that their DNA had turned negative by non-high-precision detection methods still had low viremia (LLV,DNA>20 IU/ml,IU=international unit), and LLV patients were twice as likely to develop HCC as patients with complete viral response.Patients who have received ETV or second-line NA(LAM/ADV/LdT) treatment for more than half a year to 1 year and confirmed HBV-DNA>10IU/ml by high-precision detection method are recommended to adjust the treatment plan in order to reduce the DNA load below 10IU/ml as soon as possible. It is up to the doctor, in consultation with the patient, to decide whether or not to make the adjustment.

NCT ID: NCT04724577 Recruiting - Prostate Cancer Clinical Trials

12 Fractions Carbon Ion Radiotherapy for Localized Prostate Cancer

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The arm of this study is to explore the optimal dose of 12 fractions of carbon ion radiotherapy for prostate cancer in our center.

NCT ID: NCT04724226 Recruiting - Clinical trials for Hepatocellular Carcinoma

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

C-couple
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cryoablation combined with pd-1 antibody immunotherapy (Camrelizumab) and anti-angiogenesis therapy (Apatinib) in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT04724148 Recruiting - Pain Clinical Trials

Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Portal hypertension is a common complication of chronic liver disease and is associated with most clinical consequences of cirrhosis. The most reliable method for assessing portal hypertension is the measurement of the hepatic venous pressure gradient (HVPG). The HVPG is the gold-standard methods for assessing clinically significant portal hypertension and becoming increasingly used clinically. It is useful in the differential diagnosis of portal hypertension and provides a prognostic index in cirrhotic patients. Many patients are painful and reluctant to undergo serial HVPG measurements. But interventionists are reluctant to use analgesics because they always pay more attention to the accuracy of HVPG measurements.Although Adam F. et al concluded that low-dose midazolam sedation is an option for patients undergoing serial hepatic venous pressure measurements (Hepatology 1999), the effects of using opioid analgesics alone on hepatic venous pressure measurements have not yet been defined. The objective of this study was to evaluate the effects of fentanyl on the HVPG.

NCT ID: NCT04723914 Recruiting - Lymphoma, B-Cell Clinical Trials

Dual Target CAR-T Cells in B-cell Lymphoma

CAR-T
Start date: October 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .

NCT ID: NCT04723901 Recruiting - Relapse Clinical Trials

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia

CAR-T
Start date: October 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

NCT ID: NCT04723888 Recruiting - Clinical trials for Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter

Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years.

NCT ID: NCT04723875 Recruiting - Cervical Cancer Clinical Trials

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Start date: February 1, 2021
Phase: Phase 3
Study type: Interventional

This is a prospective, phase 3 randomized controlled clinical trial. Cervical cancer patients who undergo radical surgery but do not meet criteria of adjuvant therapy according to NCCN guideline are enrolled to receive adjuvant chemotherapy. The primary endpoint was disease-free survival (DFS) rate at 3 year. The secondary endpoints were 5-year DFS, overall survival (OS) and safety.

NCT ID: NCT04723550 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

At present, in order to cope with the global pandemic of the COVID-19 virus, governments have introduced corresponding measures, COVID-19 lockdown is one of the most important measures. However, lockdown makes the management of chronic diseases (such as type 2 diabetes) more difficult, and telemedicine may be one of the solutions. We hope to explore the effect of telemedicine on blood glucose control and other prognostic indicators of young and middle-aged obese patients with type 2 diabetes who will experience isolation control.

NCT ID: NCT04722978 Recruiting - Clinical trials for Triple Negative Breast Cancer

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Start date: April 20, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.